相关实验视频

Updated: Jan 16, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

用基于iPSC的疾病建模来识别I型干扰病的潜在治疗剂

Bunki Natsumoto¹, Hirofumi Shoda^2,3, Motonori Tsuji⁴

¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Journal of clinical immunology

|September 30, 2025

概括

研究人员使用诱导多能干细胞 (iPSCs) 来建模I型干扰性病,一种罕见的遗传疾病. 他们发现阻断线粒体代谢和用三氧化 (ATO) 准PML可以减少有害的I型干扰素 (IFN) 分泌,从而提供新的治疗策略.

科学领域:

遗传学和免疫学遗传学和免疫学
干细胞生物学干细胞生物学
药物发现药物发现药物发现

背景情况:

I型干扰因子病是一种遗传性疾病,其特点是由于I型干扰因子 (IFN) 信号的升级而导致系统性炎症和神经问题.
目前对I型干扰性疾病的治疗选择有限,需要开发新的治疗策略.
诱导多能干细胞 (iPSC) 为模拟罕见遗传疾病和研究潜在疗法提供了一个有前途的平台.

研究的目的:

使用基于iPSC的疾病建模,制定一种用于识别I型干扰性病的新治疗点的策略.
研究线粒体新陈代谢和特定基因在I型干扰性病变的发病过程中的作用.
选潜在的候选药物,可以抑制过度的I型IFN分泌.

主要方法:

用基因组编辑将IFIH1 R779H变异引入iPSCs.
从iPSC衍生的树突细胞 (DC) 的RNA测序确定了差异表达基因 (DEG).
对IFN-α分泌,活性氧物种 (ROS) 和线粒体氧消耗率 (OCR) 的分析在iPSC衍生的DC中进行.
在化物化合物选的目标是人类OASL的OAS类域,随后是候选化合物的体外验证.

主要成果:

转录组分析显示IFN相关和代谢途径在IFIH1 R779H突变的iPSC衍生的DCs上调.
观察到线粒体OCR和ROS生成的增加,并且阻断线粒体新陈代谢显著减少IFN-α分泌.
PML被确定为DEG;三氧化物 (ATO),一个PML抗体,抑制IFN-α分泌.
在 silico 预测中,确定了 bisantrene,phthalylsulfathiazole 和 ganaplacide 作为 IFN-α 分泌的潜在抑制剂,通过与 OASL 域结合.

结论:

基于iPSC的疾病建模是研究I型干扰性疾病的强大平台.
针对线粒体新陈代谢和PML (例如,与ATO) 是I型干扰症的潜在治疗策略.
已识别的化合物 (双二烯,甲硫亚,加纳) 在抑制过度的IFN-α分泌方面表现有前途.

关键词:

在预测预测.艾卡迪-古提耶尔综合征 (AGS) 是一种诱导多能干细胞 (iPSCs) 是一种干细胞.用酶c域1 (IFIH1) 诱导的干扰素干扰因子疗法干扰因子疗法橄甲酸合成酶 (OAS) 家族

更多相关视频

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes

In vitro Modeling for Neurological Diseases using Direct Conversion from Fibroblasts to Neuronal Progenitor Cells and Differentiation into Astrocytes

Published on: June 10, 2021

相关概念视频

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.